Jiazhen Cui

机构：Academy of Military Medical Sciences, Cell Technology (China), Zhejiang Lab, First Affiliated Hospital Zhejiang University, Zhejiang University

发表论文 112 篇 · 总被引 1686 次 · h-index 20

代表论文

• Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial (2025 · Nature Medicine · 被引 59)
• Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (2025 · JAMA Oncology · 被引 27)
• Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma (2025 · Journal for ImmunoTherapy of Cancer · 被引 15)
• Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia (2025 · Experimental Hematology and Oncology · 被引 9)
• Sequential allogeneic HSCT after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia patients: A long-term follow-up result (2025 · Journal of Advanced Research · 被引 7)
• Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma (2025 · Bone Marrow Transplantation · 被引 4)